Recent clinical trials have shown promising results in various fields of medicine. This article summarizes key findings from recent trials.
Key points
• Teclistamab + daratumumab (TRIMM-2, phase 1b) in RRMM showed an ORR of 68.9% with a median PFS of 26.3mo. • The study also reported a high rate of grade 3/4 TEAEs, leading to the stopping of a fixed-dose cohort. • Harmoni 2 OS Press release showed an OS benefit, challenging Keytruda's dominance in the market. • Daraxonrasib's NSCLC data showed an ORR of 35% overall, with a median PFS of 8.3mo and a median OS of 16mo. • The study also reported a high rate of rash and diarrhea, with 25% of patients experiencing grade 3/4 TRAEs.
Sources
- Original post - Original source
- KolPulseAI - AI-powered clinical trial insights
- Harmoni 2 OS Press release - OS benefit in NSCLC
- Daraxonrasib's NSCLC data - NSCLC trial results
- FDA Memorandum - FDA's override of primary clinical review team's recommendation
Longevity Research - PROSPR Program
The PROSPR program is testing whether changes in intrinsic capacity can help measure treatment benefits within a few years. This includes mobility, cognitive function, and other factors.
Key points
• The PROSPR program is a key initiative in longevity research, aiming to measure treatment benefits within a few years. • The program includes mobility, cognitive function, and other factors to assess intrinsic capacity. • The study aims to provide a more accurate measure of treatment benefits, which can take decades to show.
Sources
- Original post - PROSPR program details
- ARPA_H - Agency for Research on Proving Research
Clinical Trials - AI-Human Collaboration
AI-human collaboration has shown promising results in clinical trials, with 37 amended radiology reports and 22 multidisciplinary team escalations.
Key points
• AI-human collaboration led to 37 amended radiology reports and 22 multidisciplinary team escalations. • The study showed that AI can help the expert miss fewer things, making it incredibly valuable in clinical care. • The study highlights the potential of AI-human collaboration in clinical trials.
Sources
- Original post - AI-human collaboration in clinical trials
- Meet Augustai - AI researcher
Clinical Trials - HistoPLUS
HistoPLUS is a peer-reviewed, open-access journal that has published a study on H&E cell features alone predicting FGFR3 mutation status in bladder cancer.
Key points
• HistoPLUS published a study on H&E cell features alone predicting FGFR3 mutation status in bladder cancer. • The study showed that H&E cell features alone predicted FGFR3 mutation status with an AUC of 0.80. • The study highlights the potential of HistoPLUS in clinical trials.
Sources
- Original post - HistoPLUS study details
- OwkinScience - AI-powered clinical trial insights
Clinical Trials - HD-tDCS Study
A pre-registered HD-tDCS study found that right cathodal DLPFC stimulation increased effort-related cardiac reactivity during a mental concentration task, with effects observed only in women.
Key points
• The study found that right cathodal DLPFC stimulation increased effort-related cardiac reactivity during a mental concentration task. • The effects were observed only in women, highlighting the potential of HD-tDCS in clinical trials. • The study highlights the potential of HD-tDCS in treating neurological disorders.
Sources
- Original post - HD-tDCS study details
- Neuroelectrics - Neurostimulation company